Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189298 | 0.85 | LTA4H (0.62) | LTA4HACHEMAPTSIGMAR1 | |
| SCHEMBL1005882 | 0.85 | LTA4H (0.62) | LTA4HACHEMAPTSIGMAR1 | |
| SCHEMBL1005883 | 0.85 | LTA4H (0.62) | LTA4HACHEMAPTSIGMAR1 | |
| SCHEMBL6853255 | 0.83 | ACHE (0.56) | ACHEHRH3ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL20588229 | 0.83 | ACHE (0.56) | ACHEHRH3ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL19121966 | 0.81 | NCF1 (0.39) | LTA4HHRH3ALDH1A1MAPTSIGMAR1 | |
| SCHEMBL13291354 | 0.80 | ALDH1A1 (0.63) | LTA4HACHEHRH3ALDH1A1KDM4E | |
| SCHEMBL3355426 | 0.80 | ALDH1A1 (0.63) | LTA4HACHEHRH3ALDH1A1KDM4E | |
| SCHEMBL1357166 | 0.80 | ALDH1A1 (0.63) | LTA4HACHEHRH3ALDH1A1KDM4E | |
| SCHEMBL537320 | 0.79 | SIGMAR1 (0.49) | ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2414349-A1 | 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114179-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | LTA4H 4183/4885ACHE 918/4885HRH3 763/4885 |
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LTA4H 4395/4885ACHE 4848/4885HRH3 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.